HomeCompareEARS vs VICI

EARS vs VICI: Dividend Comparison 2026

EARS yields 65.68% · VICI yields 6.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $131.3K in total portfolio value· pulled ahead in Year 10
10 years
EARS
EARS
● Live price
65.68%
Share price
$3.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$857.5K
Annual income
$214,640.91
Full EARS calculator →
VICI
VICI Properties Inc.
● Live price
6.57%
Share price
$27.12
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$988.8K
Annual income
$623,261.32
Full VICI calculator →

Portfolio growth — EARS vs VICI

📍 VICI pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEARSVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EARS + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EARS pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EARS
Annual income on $10K today (after 15% tax)
$5,582.92/yr
After 10yr DRIP, annual income (after tax)
$182,444.77/yr
VICI
Annual income on $10K today (after 15% tax)
$558.67/yr
After 10yr DRIP, annual income (after tax)
$529,772.12/yr
At 15% tax rate, VICI beats the other by $347,327.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EARS + VICI for your $10,000?

EARS: 50%VICI: 50%
100% VICI50/50100% EARS
Portfolio after 10yr
$923.1K
Annual income
$418,951.11/yr
Blended yield
45.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

EARS
No analyst data
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+16.5% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EARS buys
0
VICI buys
0
No recent congressional trades found for EARS or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEARSVICI
Forward yield65.68%6.57%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$857.5K$988.8K
Annual income after 10y$214,640.91$623,261.32
Total dividends collected$722.8K$948.4K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: EARS vs VICI ($10,000, DRIP)

YearEARS PortfolioEARS Income/yrVICI PortfolioVICI Income/yrGap
1$17,268$6,568.14$11,368$948.43+$5.9KEARS
2$29,077$10,599.97$13,339$1,493.16+$15.7KEARS
3$47,793$16,681.04$16,326$2,426.21+$31.5KEARS
4$76,764$25,624.68$21,123$4,112.15+$55.6KEARS
5$120,602$38,464.70$29,379$7,368.23+$91.2KEARS
6$185,521$56,477.71$44,804$14,191.64+$140.7KEARS
7$279,704$81,195.93$76,658$29,972.12+$203.0KEARS
8$413,691$114,407.58$150,894$71,015.81+$262.8KEARS
9$600,792$158,142.40$350,814$193,582.47+$250.0KEARS
10← crossover$857,488$214,640.91$988,809$623,261.32$131.3KVICI

EARS vs VICI: Complete Analysis 2026

EARSStock

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.

Full EARS Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this EARS vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EARS vs SCHDEARS vs JEPIEARS vs OEARS vs KOEARS vs MAINEARS vs NNNEARS vs EPRTEARS vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.